Anemia and Abnormal Levels of Hemoglobin Correlated With Dementia, Alzheimer Disease
Low and high hemoglobin levels were associated with increased risk for dementia, white matter hyperintensity volume, and structural connectivity.
Anemias
Autoantibodies May Contribute to ESA Hyporesponsiveness in HD
In a study, autoantibodies to the erythropoietin receptor were detected in some patients on maintenance hemodialysis, and this correlated with hyporesponsiveness to erythropoiesis-stimulating agents.
Authors Suggest Prudent Approach to ESA Use in Patients With Both CKD and Cancer
In anemic kidney disease patients with cancer, reviewers suggest using ESA to minimize symptoms without exceeding a hemoglobin target of 10 g/dL.
Cardiovascular Risks Similar for Monthly, Short-Acting ESAs
Over a median 5.1 years, similar proportions of patients who received monthly methoxy polyethylene glycol epoetin beta arm and a reference group treated with conventional ESAs experienced major cardiovascular events and death.
High-Dose IV Iron Appears Safe in Hemodialysis Patients
Meta-analysis reveals no statistically significant increase in the risks of infection, cardiovascular events, hospitalizations, or death with the use of high-dose parenteral iron.
Efficacy, Safety of Hypoxia-Inducible Factor Activators in Renal Anemia
The first HIF-PHI, roxadustat, was recently approved in China.
Review: Individualized Renal Anemia Care Important
Measuring health-related quality of life should be routine patient care, according to a new review.
PIVOTAL Trial Provides Important Guidance on IV Iron Use in ESRD
Recent review says findings from the PIVOTAL trial should allay concerns about the use of intravenous iron therapy in patients with end-stage renal disease suffering from anemia.
Anemia Severity May Influence Vascular Access Outcomes, Mortality
In a study of chronic kidney disease patients undergoing vascular access surgery for hemodialysis, severe preoperative anemia was associated with worse outcomes.
New Oral Therapy Approved for Iron Deficiency in Adults
The FDA has approved Accrufer (ferric maltol; Shield Therapeutics) for the treatment of iron deficiency in adults.
Next post in Anemia
